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Background: Vitamin D (VitD) deficiency is common and has adverse effects in multiple organ systems. Recent population based studies have 
linked low VitD levels to CV morbidity and mortality. The aim of this post hoc analysis of the TNT trial was to determine the effect of serum VitD levels 
on CV morbidity and death in a population of statin-treated patients with stable CHD.
Methods: A total of 10,001 stable CHD patients were randomized to atorvastatin 80 mg vs 10 mg and followed for a median of 4.9 years. This 
analysis includes 1509 patients (497 with a subsequent CV event; 1012 without an event) who had VitD levels determined by radioimmunoassay at 
baseline and 1 year. Event rates were analyzed by VitD quartile and modeled with VitD as a continuous variable.
Results: Median VitD levels at baseline were 30.4 ng/ml in cases and controls (IQR 23.2 and 38.4 in cases; 22.8 and 38.0 in controls, P=NS) and 
did not differ by assigned treatment group. Deficiency (<30 ng/ml) was present in 733/1509 (49%) of patients. Compared to baseline, VitD levels 
at 1 year were 7% lower in both treatment groups. There was no relationship between baseline VitD levels (Table) or change in VitD levels (data 
not shown) and CV events or mortality. Modeling events with VitD as a continuous variable similarly showed no relationship of VitD to events. These 
findings held true following adjustment for seasonal variations in VitD.
Conclusion: In patients with stable CHD treated with atorvastatin, VitD serum levels do not predict future CV events or mortality.
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend
CV events* Referent
1.027
(0.798, 1.322)
1.025
(0.795, 1.322)
1.035
(0.805, 1.330)
0.9940
Death Referent
0.617
(0.395, 0.964)
0.844
(0.549, 1.298)
0.737
(0.481, 1.129)
0.1795
*CHD death, nonfatal MI, resuscitated cardiac arrest, and stroke
Data adjusted for seasonal variations in VitD
